Pub Date : 2020-12-31DOI: 10.33696/HAEMATOLOGY.1.014
A. Crisci, Carlo Alberto Minniti, A. Conte, M. Crisci, Federica Cardillo
Alessandro Crisci1,2,3*, Carlo Alberto Minniti4, Antonella Conte5, Michela Crisci6, Federica Cardillo7 1School of Medicine, University of Salerno Italy, 84084 Fisciano SA, Italy 2Unit of Dermosurgery Cutaneous Transplantations and Hard-to-HealWound,“Villa Fiorita”Private Hospital, 81031 Aversa CE, Italy 3Institute for the Studies and Care of Diabetics, Abetaia, 81020 Casagiove CE, Italy; 4 Colonel Veterinarian, Director of the Veterinary Service, HQ Carabinieri Army, Roma, Italy 5Veterinarian Freelancer, Caserta, Italy 6Faculty of Medicine and Surgery, Vasile Goldis Western University of Arad, 310025 Arad, Romania; 7Veterinarian Freelancer, Sulmona (AQ), Italy *Correspondence should be addressed to Alessandro Crisci; alcrisci@unisa.it
{"title":"Second Generation Platelet Concentrates - L-PRF (Fibrin Rich in Platelets and Leukocytes) and Its Derivatives (A-PRF, I-PRF)-: Morphological Characteristics to be Used in Modern Regenerative Surgery. Experimental Research","authors":"A. Crisci, Carlo Alberto Minniti, A. Conte, M. Crisci, Federica Cardillo","doi":"10.33696/HAEMATOLOGY.1.014","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.014","url":null,"abstract":"Alessandro Crisci1,2,3*, Carlo Alberto Minniti4, Antonella Conte5, Michela Crisci6, Federica Cardillo7 1School of Medicine, University of Salerno Italy, 84084 Fisciano SA, Italy 2Unit of Dermosurgery Cutaneous Transplantations and Hard-to-HealWound,“Villa Fiorita”Private Hospital, 81031 Aversa CE, Italy 3Institute for the Studies and Care of Diabetics, Abetaia, 81020 Casagiove CE, Italy; 4 Colonel Veterinarian, Director of the Veterinary Service, HQ Carabinieri Army, Roma, Italy 5Veterinarian Freelancer, Caserta, Italy 6Faculty of Medicine and Surgery, Vasile Goldis Western University of Arad, 310025 Arad, Romania; 7Veterinarian Freelancer, Sulmona (AQ), Italy *Correspondence should be addressed to Alessandro Crisci; alcrisci@unisa.it","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43716086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.33696/HAEMATOLOGY.1.011
A. Khodair, M. A. Alsafi
72 Breast cancer is the most frequent malignancy in females. Due to its major impact on the population, this disease represents a critical public health problem that requires further research at the molecular level to define its prognosis and specific treatment. Basic research is required to accomplish this task and this involves cell lines as they can be widely used in many aspects of laboratory research and, particularly, as in vitro models in cancer research. MCF-7 is a commonly used breast cancer cell line, that has been promoted for more than 40 years by multiple research groups but its characteristics have never been gathered in a consistent review article. The current paper provides a broad description of the MCF7 cell line, including the molecular profile, proliferation, migration, invasion, spheroid formation, its involvement in angiogenesis and lymphangiogenesis, and its interaction with the mesenchymal stem cells [1].
{"title":"Anticancer Activity of S-Glycosylated Quinazoline Derivatives","authors":"A. Khodair, M. A. Alsafi","doi":"10.33696/HAEMATOLOGY.1.011","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.011","url":null,"abstract":"72 Breast cancer is the most frequent malignancy in females. Due to its major impact on the population, this disease represents a critical public health problem that requires further research at the molecular level to define its prognosis and specific treatment. Basic research is required to accomplish this task and this involves cell lines as they can be widely used in many aspects of laboratory research and, particularly, as in vitro models in cancer research. MCF-7 is a commonly used breast cancer cell line, that has been promoted for more than 40 years by multiple research groups but its characteristics have never been gathered in a consistent review article. The current paper provides a broad description of the MCF7 cell line, including the molecular profile, proliferation, migration, invasion, spheroid formation, its involvement in angiogenesis and lymphangiogenesis, and its interaction with the mesenchymal stem cells [1].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43569293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.33696/HAEMATOLOGY.1.016
Katarzyna Piadel, A. Dalgleish, P. Smith
Gemcitabine is a synthetic pyrimidine nucleoside analogue which is administered intravenously as a chemotherapeutic to treat numerous cancers. Gemcitabine requires transport into cells and activation by phosphorylation, the resulting gemcitabine triphosphate is incorporated into newly synthesized DNA during cell division, inhibiting further DNA synthesis and causing cell death. Gemcitabine is used to treat cancers including those of the pancreas, lung, breast, colon, and ovary either as first or second line treatments as a single agent or in combination.
{"title":"Gemcitabine in the Era of Cancer Immunotherapy","authors":"Katarzyna Piadel, A. Dalgleish, P. Smith","doi":"10.33696/HAEMATOLOGY.1.016","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.016","url":null,"abstract":"Gemcitabine is a synthetic pyrimidine nucleoside analogue which is administered intravenously as a chemotherapeutic to treat numerous cancers. Gemcitabine requires transport into cells and activation by phosphorylation, the resulting gemcitabine triphosphate is incorporated into newly synthesized DNA during cell division, inhibiting further DNA synthesis and causing cell death. Gemcitabine is used to treat cancers including those of the pancreas, lung, breast, colon, and ovary either as first or second line treatments as a single agent or in combination.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43194063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.33696/HAEMATOLOGY.1.019
M. Brunner, Luke D. Zurbriggen, Julie E. Chang
Intravascular B cell lymphoma (IVBCL) is notoriously difficult to diagnose as the clinical manifestations are protean, and the patterns seen with routine labs and imaging are non-specific [1]. Furthermore, the disease follows an aggressive course and is often fatal within a matter of weeks to months from symptom onset, unless recognized and treated appropriately [2]. This has historically meant that diagnosis was made at autopsy for many patients. Over the past few decades, however, scientific and clinical literature have slowly accumulated to better characterize and raise clinical awareness of this disease. In this paper, we will review the characteristics that make this diagnosis challenging, and then discuss new and emerging diagnostic avenues.
{"title":"Unmasking the Master of Disguise: Defining Advancements in Diagnosis of Intravascular Large B-cell Lymphoma","authors":"M. Brunner, Luke D. Zurbriggen, Julie E. Chang","doi":"10.33696/HAEMATOLOGY.1.019","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.019","url":null,"abstract":"Intravascular B cell lymphoma (IVBCL) is notoriously difficult to diagnose as the clinical manifestations are protean, and the patterns seen with routine labs and imaging are non-specific [1]. Furthermore, the disease follows an aggressive course and is often fatal within a matter of weeks to months from symptom onset, unless recognized and treated appropriately [2]. This has historically meant that diagnosis was made at autopsy for many patients. Over the past few decades, however, scientific and clinical literature have slowly accumulated to better characterize and raise clinical awareness of this disease. In this paper, we will review the characteristics that make this diagnosis challenging, and then discuss new and emerging diagnostic avenues.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44880136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.33696/HAEMATOLOGY.1.017
G. Zugmaier
121 In the article by Gerhard Zugmaier, Antibodies in hematology by the example of acute lymphoblastic leukemia, Der Internist 10 (2019) 1032–1035 [1], the application of antibodies in hematology was described by using the example of acute lymphoblastic leukemia. Antibodies have become an essential element of treatment for patients with hematological tumors. This concept was developed more than 100 years ago in a different context [2]. The German physician Paul Ehrlich (1854-1915) said, that for the defense against bacteria “antibodies” were be responsible [2,4]. In the antibodies Ehrlich saw therapeutic compounds, that like “magic bullets” would find their target and only destroy this target without affecting the organism. Paul Ehrlich became inspired by a scene in the German opera “Der Freischütz” (“The marksman”) by the composer Carl Maria von Weber [3]. In this opera a certain kind of bullets, “free bullets”, which were magic bullets, played a major role, because they always found their target. In 1878 Paul Ehrlich became resident and later attending physician at the Charité in Berlin. There, he worked closely together with Robert Koch, Emil von Behring, and Shibasaburo Kitasato. The chairman of the department, the famous internist Theodor von Frerichs, gave Paul Ehrlich enough space to conduct his experiments. Starting from 1882 Ehrlich investigated the acid resistance of the tuberculosis mycobacterium just discovered by Robert Koch and developed a method of dyeing the mycobacterium, thereby being able to detect it in the organism. Koch and Frerichs were important supporters of Ehrlich [4]. In 1890, Ehrlich was appointed by Koch to a position at the newly founded Institute for infectious Disease, the Robert Koch Institute. Ehrlich’s groundbreaking research in immunology started at that time. Later, in 1899, Ehrlich was appointed as Chairman of the newly found Institute for Experimental Therapy in Frankfurt, the Georg Speyer Haus, in which until this day important research has been conducted. There he continued his groundbreaking research in Immunology and Cancer Research. In 1908, Paul Ehrlich received the Nobel prize for Medicine [4]. Ehrlich’s great ability for abstract concepts enabled the creation of terms such as ‘receptor’ [2]. In this context he also developed the concept of “magic bullets”, which are drugs that move straight to their target. Targeted compounds attack pathogens that express the target and leave tissue alone that does not express the target [2]. It turned out later that the concept of magic bullets was not confined to bacterial infections and could be extrapolated from infectious disease to malignant tumors. Surface antigens on tumor cells could serve as target of these magic bullets.
{"title":"Targeted Immune Therapy as Example of Paul Ehrlich’s “Magic Bullets” Developed More than 100 Years Ago","authors":"G. Zugmaier","doi":"10.33696/HAEMATOLOGY.1.017","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.017","url":null,"abstract":"121 In the article by Gerhard Zugmaier, Antibodies in hematology by the example of acute lymphoblastic leukemia, Der Internist 10 (2019) 1032–1035 [1], the application of antibodies in hematology was described by using the example of acute lymphoblastic leukemia. Antibodies have become an essential element of treatment for patients with hematological tumors. This concept was developed more than 100 years ago in a different context [2]. The German physician Paul Ehrlich (1854-1915) said, that for the defense against bacteria “antibodies” were be responsible [2,4]. In the antibodies Ehrlich saw therapeutic compounds, that like “magic bullets” would find their target and only destroy this target without affecting the organism. Paul Ehrlich became inspired by a scene in the German opera “Der Freischütz” (“The marksman”) by the composer Carl Maria von Weber [3]. In this opera a certain kind of bullets, “free bullets”, which were magic bullets, played a major role, because they always found their target. In 1878 Paul Ehrlich became resident and later attending physician at the Charité in Berlin. There, he worked closely together with Robert Koch, Emil von Behring, and Shibasaburo Kitasato. The chairman of the department, the famous internist Theodor von Frerichs, gave Paul Ehrlich enough space to conduct his experiments. Starting from 1882 Ehrlich investigated the acid resistance of the tuberculosis mycobacterium just discovered by Robert Koch and developed a method of dyeing the mycobacterium, thereby being able to detect it in the organism. Koch and Frerichs were important supporters of Ehrlich [4]. In 1890, Ehrlich was appointed by Koch to a position at the newly founded Institute for infectious Disease, the Robert Koch Institute. Ehrlich’s groundbreaking research in immunology started at that time. Later, in 1899, Ehrlich was appointed as Chairman of the newly found Institute for Experimental Therapy in Frankfurt, the Georg Speyer Haus, in which until this day important research has been conducted. There he continued his groundbreaking research in Immunology and Cancer Research. In 1908, Paul Ehrlich received the Nobel prize for Medicine [4]. Ehrlich’s great ability for abstract concepts enabled the creation of terms such as ‘receptor’ [2]. In this context he also developed the concept of “magic bullets”, which are drugs that move straight to their target. Targeted compounds attack pathogens that express the target and leave tissue alone that does not express the target [2]. It turned out later that the concept of magic bullets was not confined to bacterial infections and could be extrapolated from infectious disease to malignant tumors. Surface antigens on tumor cells could serve as target of these magic bullets.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"110 30","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41251378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.33696/HAEMATOLOGY.1.020
A. Khodair, A. Attia, E. Gendy, Y. Elshaier, M. El-Magd
Ahmed I. Khodair1*, Adel M. Attia1, Eman A. Gendy1, Yaseen A. M. M. Elshaier2, Mohammed A. El-Magd3 1Chemistry Department, Faculty of Science, kafrelshiekh University, El-Geish Street, kafrelshiekh, Post Box 33516, Egypt 2Department of Organic and Medicinal chemistry, Faculty of Pharmacy, University of Sadat City, Menoufiya, 32897, Egypt 3Anatomy Department, Faculty of Veterinary Medicine, Kafrelshiekh University, El-Geish Street, kafrelshiekh, Post Box 33516, Egypt
Ahmed I. Khodair1*， Adel M. Attia1, Eman A. Gendy1, Yaseen A. M. Elshaier2, Mohammed A. El-Magd3 1埃及kafrelsheikh El-Geish街，邮政信箱33516;2埃及Menoufiya, 32897;萨达特市大学药学院有机与药物化学系;3埃及kafrelsheikh El-Geish街，邮政信箱33516
{"title":"Anticancer and Antiviral Activity of the Pyridine-Biphenyl Glycoside System","authors":"A. Khodair, A. Attia, E. Gendy, Y. Elshaier, M. El-Magd","doi":"10.33696/HAEMATOLOGY.1.020","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.020","url":null,"abstract":"Ahmed I. Khodair1*, Adel M. Attia1, Eman A. Gendy1, Yaseen A. M. M. Elshaier2, Mohammed A. El-Magd3 1Chemistry Department, Faculty of Science, kafrelshiekh University, El-Geish Street, kafrelshiekh, Post Box 33516, Egypt 2Department of Organic and Medicinal chemistry, Faculty of Pharmacy, University of Sadat City, Menoufiya, 32897, Egypt 3Anatomy Department, Faculty of Veterinary Medicine, Kafrelshiekh University, El-Geish Street, kafrelshiekh, Post Box 33516, Egypt","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47943039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-13DOI: 10.33696/haematology.1.007
Mahdieh Motie, R. Dehnavieh, Khalil Kalavani
54 COVID-19 has challenged global health and affected many countries. The disease had infected more than 16 million people and killed over 650,000 ones by the end of July 2020. According to Sahu et al., COVID-19 epidemic is the third most common coronavirus in the 21st century, resulting in numerous deaths all over the world [1]. It has caused severe psychological stress and increased hospital visits along with increased tiredness and burnout of medical staff. The disease has also raised many problems for the management of hospitals and diagnostic-treatment centers, so that many of them have no capacity to receive patients [2].
{"title":"Management of Diagnostic and Treatment Centers in the Second Wave of COVID-19","authors":"Mahdieh Motie, R. Dehnavieh, Khalil Kalavani","doi":"10.33696/haematology.1.007","DOIUrl":"https://doi.org/10.33696/haematology.1.007","url":null,"abstract":"54 COVID-19 has challenged global health and affected many countries. The disease had infected more than 16 million people and killed over 650,000 ones by the end of July 2020. According to Sahu et al., COVID-19 epidemic is the third most common coronavirus in the 21st century, resulting in numerous deaths all over the world [1]. It has caused severe psychological stress and increased hospital visits along with increased tiredness and burnout of medical staff. The disease has also raised many problems for the management of hospitals and diagnostic-treatment centers, so that many of them have no capacity to receive patients [2].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47266707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.33696/haematology.1.015
Asma Ayari, Roddy S O'Connor
The renewed interest in understanding how activated T cells alter their metabolism to support their growth and differentiation has led to several innovative advances in synthetic biology; culminating in a number of genetic and pharmacologic approaches aimed at improving the antitumor function of adoptively transferred T cells. Indeed, the growing field of immunometabolism has accelerated rapidly giving rise to exciting discoveries and exploratory studies revealing how T cells balance metabolic adaptations in response to intrinsic and extrinsic regulatory cues. Central to this body of work, we showed how chimeric antigen receptors (CAR)-induced metabolic reprogramming is an important determinant of efficacy and clinical outcome in blood-based malignancies [1]. CAR T-cell production involves a rigorous, and systematic ex-vivo expansion regime involving activation; genetic modification with either a CAR or tumor-specific T cell receptor (TCR); and proliferative phase which often lasts 14 days. As CAR T-cells progressively differentiate over time in culture, a process that impairs engraftment and potency following adoptive transfer, it’s surprising that the metabolic composition of clinical grade cell culture mediums has been largely understudied. Increasing evidence suggests that subtle adjustments in medium formulation can have a dramatic impact on T cell bioactivity and anti-tumor function in several preclinical models of cancer. In a recent article, we provide direct evidence that standard medium formulations are suboptimal, and introduce a serum-free, concentrated, platelet extract as a superior alternative to human serum in clinical-grade medium for CAR T-cells [2].
{"title":"Citius, Altius, Fortius: Performance in a Bottle for CAR T-Cells.","authors":"Asma Ayari, Roddy S O'Connor","doi":"10.33696/haematology.1.015","DOIUrl":"https://doi.org/10.33696/haematology.1.015","url":null,"abstract":"The renewed interest in understanding how activated T cells alter their metabolism to support their growth and differentiation has led to several innovative advances in synthetic biology; culminating in a number of genetic and pharmacologic approaches aimed at improving the antitumor function of adoptively transferred T cells. Indeed, the growing field of immunometabolism has accelerated rapidly giving rise to exciting discoveries and exploratory studies revealing how T cells balance metabolic adaptations in response to intrinsic and extrinsic regulatory cues. Central to this body of work, we showed how chimeric antigen receptors (CAR)-induced metabolic reprogramming is an important determinant of efficacy and clinical outcome in blood-based malignancies [1]. CAR T-cell production involves a rigorous, and systematic ex-vivo expansion regime involving activation; genetic modification with either a CAR or tumor-specific T cell receptor (TCR); and proliferative phase which often lasts 14 days. As CAR T-cells progressively differentiate over time in culture, a process that impairs engraftment and potency following adoptive transfer, it’s surprising that the metabolic composition of clinical grade cell culture mediums has been largely understudied. Increasing evidence suggests that subtle adjustments in medium formulation can have a dramatic impact on T cell bioactivity and anti-tumor function in several preclinical models of cancer. In a recent article, we provide direct evidence that standard medium formulations are suboptimal, and introduce a serum-free, concentrated, platelet extract as a superior alternative to human serum in clinical-grade medium for CAR T-cells [2].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"1 3","pages":"103-106"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25343843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.33696/haematology.2.022
{"title":"Lower 24-Month Relative Survival among Black Patients with Non- Hodgkin’s Lymphoma: An Analysis of the SEER Data 1997-20","authors":"","doi":"10.33696/haematology.2.022","DOIUrl":"https://doi.org/10.33696/haematology.2.022","url":null,"abstract":"","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69670003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：